Access to Leronlimab for Patients with Advanced Triple-Negative Breast Cancer

Inclusion Criteria

• Adults over 18 years old.
• Diagnosed with advanced or metastatic triple-negative breast cancer (TNBC) that has progressed after standard treatments.
• Unable to receive standard treatments due to side effects or lack of options.
• Willing to provide a new tumor sample if an old one is not available.
• Cannot join any current clinical trials for leronlimab.
• Have good organ and bone marrow function as determined by the doctor.
• Have a performance status score of 0 to 2, meaning fully active or restricted in physically strenuous activity but ambulatory.
• Agree to use two forms of birth control or abstain from sex during the study and for 4 months after the last dose.
• Willing to follow study requirements and attend follow-up visits.
• Able to understand and sign a consent form before joining the study.

Exclusion Criteria

• History of allergic reactions to similar drugs as leronlimab.
• Have active cancer spread to the brain or spinal fluid, unless previously treated and stable.
• Have uncontrolled illnesses like infections or heart failure that could interfere with treatment.
• Currently participating in another clinical trial.
• Pregnant or breastfeeding.
• Any condition that could interfere with safe treatment.
• Have psychiatric or substance abuse issues that could affect participation.